MHCII Expression on Peripheral Blood Monocytes in Canine Lymphoma: An Impact of Glucocorticoids

Overview

Journal Animals (Basel)

Date 2022 Aug 26

PMID 36009726

Authors

Alicja Rzepecka

Dariusz Jagielski

Anna Cywinska

Rafal Sapierzynski

Magdalena Zmigrodzka

Olga Witkowska-Pilaszewicz

Anna Winnicka

Affiliations

Soon will be listed here.

Abstract

An increase in the percentage of monocytes with reduced HLA-DR expression and immunosuppressive properties has been reported in numerous human neoplastic diseases, including lymphoma. However, there are no analogous studies on phenotypical variations in the peripheral blood monocytes in dogs with lymphoma. The aim of this study was to determine the difference in the expression of the MHCII molecule on peripheral blood monocytes in dogs with lymphoma before any treatment (NRG) and in dogs that had previously received glucocorticoids (RG) in comparison to healthy dogs. Flow cytometry immunophenotyping of peripheral blood leukocytes was performed using canine-specific or cross-reactive antibodies against CD11b, CD14 and MHCII. In the blood of dogs with lymphoma (NRG and RG), compared to that of healthy ones, the MHCII+ and MHCII- monocytes ratio was changed due to an increase in the percentage of MHCII- monocytes. The number of MHCII- monocytes was significantly higher only in RG dogs compared to healthy ones, which might result from the release of these cells from the blood marginal pool due to the action of glucocorticoids. Our results encourage further studies to assess if changes in MHCII expression affect immune status in dogs with lymphoma.

Citing Articles

A review of CD4 T cell differentiation and diversity in dogs.

Lang H, Osum K, Friedenberg S Vet Immunol Immunopathol. 2024; 275:110816.

PMID: 39173398 PMC: 11421293. DOI: 10.1016/j.vetimm.2024.110816.

References

Jacobsen C, Aasted B, Broe M, Petersen J . Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten different animal species. Vet Immunol Immunopathol. 1993; 39(4):461-6. DOI: 10.1016/0165-2427(93)90075-f. View

Gupta M, Han J, Stenson M, Maurer M, Wellik L, Hu G . Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood. 2012; 119(12):2844-53. PMC: 3327462. DOI: 10.1182/blood-2011-10-388538. View

Javeed N, Gustafson M, Dutta S, Lin Y, Bamlet W, Oberg A . Immunosuppressive CD14HLA-DR monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes. Oncoimmunology. 2017; 6(1):e1252013. PMC: 5283619. DOI: 10.1080/2162402X.2016.1252013. View

Ono S, Tsujimoto H, Matsumoto A, Ikuta S, Kinoshita M, Mochizuki H . Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am J Surg. 2004; 188(2):150-6. DOI: 10.1016/j.amjsurg.2003.12.067. View

de Waal Malefyt R, Haanen J, Spits H, Roncarolo M, Te Velde A, Figdor C . Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991; 174(4):915-24. PMC: 2118975. DOI: 10.1084/jem.174.4.915. View

Thibodeau J, Bourgeois-Daigneault M, Huppe G, Tremblay J, Aumont A, Houde M . Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. Eur J Immunol. 2008; 38(5):1225-30. PMC: 2759377. DOI: 10.1002/eji.200737902. View

Lautscham E, Kessler M, Ernst T, Willimzig L, Neiger R . Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma. Vet Rec. 2017; 180(12):303. DOI: 10.1136/vr.104077. View

Weiss D, Welle M, Mortiz A, Walcheck B . Evaluation of leukocyte cell surface markers in dogs with septic and nonseptic inflammatory diseases. Am J Vet Res. 2004; 65(1):59-63. DOI: 10.2460/ajvr.2004.65.59. View

Koppelman B, Neefjes J, De Vries J, de Waal Malefyt R . Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity. 1998; 7(6):861-71. DOI: 10.1016/s1074-7613(00)80404-5. View

10.

OGarra A, Stapleton G, Dhar V, Pearce M, Schumacher J, Rugo H . Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol. 1990; 2(9):821-32. DOI: 10.1093/intimm/2.9.821. View

11.

Benjamin D, Knobloch T, Dayton M . Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood. 1992; 80(5):1289-98. View

12.

Vuk-Pavlovic S, Bulur P, Lin Y, Qin R, Szumlanski C, Zhao X . Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate. 2009; 70(4):443-55. PMC: 2935631. DOI: 10.1002/pros.21078. View

13.

Thelemann C, Eren R, Coutaz M, Brasseit J, Bouzourene H, Rosa M . Interferon-γ induces expression of MHC class II on intestinal epithelial cells and protects mice from colitis. PLoS One. 2014; 9(1):e86844. PMC: 3904943. DOI: 10.1371/journal.pone.0086844. View

14.

Quezada S, Peggs K . Tumor-reactive CD4+ T cells: plasticity beyond helper and regulatory activities. Immunotherapy. 2011; 3(8):915-7. DOI: 10.2217/imt.11.83. View

15.

Winkler M, Rissiek A, Priefler M, Schwedhelm E, Robbe L, Bauer A . Human leucocyte antigen (HLA-DR) gene expression is reduced in sepsis and correlates with impaired TNFα response: A diagnostic tool for immunosuppression?. PLoS One. 2017; 12(8):e0182427. PMC: 5542660. DOI: 10.1371/journal.pone.0182427. View

16.

Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H . Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol. 2000; 79(3):110-3. DOI: 10.1007/s002770050564. View

17.

Zandvliet M . Canine lymphoma: a review. Vet Q. 2016; 36(2):76-104. DOI: 10.1080/01652176.2016.1152633. View

18.

Giroux M, Schmidt M, Descoteaux A . IFN-gamma-induced MHC class II expression: transactivation of class II transactivator promoter IV by IFN regulatory factor-1 is regulated by protein kinase C-alpha. J Immunol. 2003; 171(8):4187-94. DOI: 10.4049/jimmunol.171.8.4187. View

19.

Rocha N, Neefjes J . MHC class II molecules on the move for successful antigen presentation. EMBO J. 2007; 27(1):1-5. PMC: 2206127. DOI: 10.1038/sj.emboj.7601945. View

20.

Lin Y, Gustafson M, Bulur P, Gastineau D, Witzig T, Dietz A . Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood. 2010; 117(3):872-81. PMC: 3035079. DOI: 10.1182/blood-2010-05-283820. View